SUPERNUS PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2021-12-31, per its 10-K filed 2022-04-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2022-04-13
- 2021-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2021-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $20.07M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-04-13 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 |
| 2021-03-31 | $20.07M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $20.87M 10-K · filed 2022-04-13 |
| 2020-09-30 | $21.68M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $22.48M 10-Q · filed 2020-08-17 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |